Expand Content

Mikkael Sekeres, MD, MS


Mikkael Sekeres, MD, MS
Department: Hematology and Oncology
Location: Cleveland Clinic Main Campus
Mail Code R35
9500 Euclid Avenue
Cleveland, OH 44195
Mikkael Sekeres, MD, MS
Department: Translational Hematology and Oncology Research
Location: Cleveland Clinic Main Campus
Mail Code R35
9500 Euclid Avenue
Cleveland, OH 44195
Type of Doctor:
Adults Only

Professional Highlights

  • Director, Leukemia Program
  • Co-Chair, Medical Advisory Board, Aplastic Anemia and Myelodysplastic Syndromes International Foundation
  • Member, Oncologic Drugs Advisory Committee, F.D.A.
  • Member, National Cancer Institute PDQ Adult Treatment Editorial Board
  • Editorial Boards, Journal of Clinical Oncology, Current Hematologic Malignancy Reports, Oncology Times, Blood Cancer Journal, Nature: Leukemia
  • Reviewer, Blood, Cancer, Lancet, Clinical Cancer Research, Oncology, Leukemia Research, British Journal of Hematology, Cancer Investigation, Bone Marrow Transplantation

Education & Fellowships

Fellowship - Dana-Farber Cancer Institute Harvard Medical School
Boston, MA USA
Residency - Massachusetts General Hospital
Internal Medicine
Boston, MA USA
Graduate - University of Pennsylvania
Clinical Epidemiology
Philadelphia, PA USA
Medical School - University of Pennsylvania School of Medicine
Philadelphia, PA USA
Undergraduate - University of Pennsylvania
Philadelphia, PA USA


  • Internal Medicine- Medical Oncology

Specialty Interests

Leukemia, myelodysplastic syndromes, bone marrow failure syndromes, clinical trials, cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, leukemia

Awards & Honors

  • Phi Beta Kappa, University of Pennsylvania, 1991
  • Magna cum Laude, University of Pennsylvania, 1991
  • “Bridging the Gaps” Community Service Achievement Award, University of Pennsylvania School of Medicine, 1995
  • Alpha Omega Alpha, University of Pennsylvania School of Medicine, 1995
  • American Federation for Clinical Research Award, University of Pennsylvania School of Medicine, 1996
  • Study Sections, RFA-HL-04-033 (Myelodysplastic Syndromes) and RFA-HL-04-034 (Myeloproliferative Disorders), National Heart, Lung and Blood Institute, 2005
  • Moderator, American Society of Hematology Annual Meeting, Myelodysplastic Syndromes: Clinical Studies session, 2005, 2007, 2011
  • Moderator, American Society of Hematology Annual Meeting, Acute Myeloid Leukemia: Therapies Excluding Transplant, 2008
  • Scientific Discussant, American Society of Clinical Oncology Annual Meeting: Leukemia, Myelodysplasia, and Transplantation Session, 2008
  • Education Session chair, American Association of Blood Bankers Annual Meeting: Myelodysplastic Syndromes, 2009
  • Education Session chair, American Society of Hematology Annual Meeting: Myelodysplastic Syndromes, 2009
  • Best Doctors, Cleveland Magazine, 2008, 2009, 2010, 2011;
  • Top Doctors of America, Castle Connolly 2010, 2011
  • Teacher of the Year, Hematology/Medical Oncology Fellowship Program, Cleveland Clinic Taussig Cancer Institute (2010)
  • National Institutes of Health Merit Award – for work with PDQ Editorial Board, National Cancer Institute (2010)
  • Gold Award - American Society of Healthcare Publication Editors, Best Regular Column, Oncology Times (2011)

Additional Training

  • Coursework, Harvard School of Public Health, 2000
  • Leading in Healthcare course, Cleveland Clinic, 2008


  • American Society of Hematology
  • Southwest Oncology Group, Leukemia Committee
  • American Society of Clinical Oncology

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 1/21/2015, Dr. Sekeres has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English